Literature DB >> 9550401

Identification of shared tumor-associated antigen peptides between two spontaneous lung carcinomas.

O Mandelboim1, E Bar-Haim, E Vadai, M Fridkin, L Eisenbach.   

Abstract

CTLs recognize antigenic peptides bound to MHC class I Ags on the cell surface of tumor cells. Tumor-associated Ag (TAA) peptides are 8 to 10 amino acids long and can be derived from normal, mutated, or viral proteins. The majority of T cell-defined Ags have been identified in human melanoma cells. These were shown to be commonly expressed by different allogeneic melanomas that share the same MHC molecule. We have recently isolated Kb-restricted TAA peptides, which are mutations of the gap junction protein connexin 37, from the spontaneous C57BL/6 Lewis lung carcinoma (3LL). These peptides, named MUT 1 and MUT 2, serve as CTL epitopes and can induce CTL activity in vivo. Using CTL cross-reaction assays, peptide extraction, HPLC fractionation, and reverse transcriptase-PCR amplification, we show that clones of another spontaneous C57BL/6 lung carcinoma, CMT 64, share TAA peptides with the 3LL carcinoma. Vaccination with synthetic MUT 1 or MUT 2 induces CTLs that efficiently lyse CMT 64-derived clones, protects mice from CMT 64 metastasis, and affords therapy of established CMT 64 metastases. Hence, shared CTL epitopes exist between two spontaneous murine lung carcinomas.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9550401

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor.

Authors:  Vasso Apostolopoulos; Elizabeth Yuriev; Paul A Ramsland; Jodie Halton; Carla Osinski; Wenjun Li; Magdalena Plebanski; Hans Paulsen; Ian F C McKenzie
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

2.  Simultaneous activation of T helper function can augment the potency of dendritic cell-based cancer immunotherapy.

Authors:  Koji Teramoto; Yasuhiko Ohshio; Takuya Fujita; Jun Hanaoka; Keiichi Kontani
Journal:  J Cancer Res Clin Oncol       Date:  2013-02-15       Impact factor: 4.553

3.  Multivalent Forms of the Notch Ligand DLL-1 Enhance Antitumor T-cell Immunity in Lung Cancer and Improve Efficacy of EGFR-Targeted Therapy.

Authors:  Asel K Biktasova; Duafalia F Dudimah; Roman V Uzhachenko; Kyungho Park; Anwari Akhter; Rajeswara R Arasada; Jason V Evans; Sergey V Novitskiy; Elena E Tchekneva; David P Carbone; Anil Shanker; Mikhail M Dikov
Journal:  Cancer Res       Date:  2015-09-24       Impact factor: 12.701

4.  Induction of cytolytic anti-Gal antibodies in alpha-1,3-galactosyltransferase gene knockout mice by oral inoculation with Escherichia coli O86:B7 bacteria.

Authors:  Karla J Posekany; H Keith Pittman; John F Bradfield; Carl E Haisch; Kathryn M Verbanac
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

5.  Determinant roles of dendritic cell-expressed Notch Delta-like and Jagged ligands on anti-tumor T cell immunity.

Authors:  Elena E Tchekneva; Mounika U L Goruganthu; Roman V Uzhachenko; Portia L Thomas; Anneliese Antonucci; Irina Chekneva; Michael Koenig; Longzhu Piao; Anwari Akhter; Maria Teresa P de Aquino; Parvathi Ranganathan; Nicholas Long; Thomas Magliery; Anna Valujskikh; Jason V Evans; Rajeswara R Arasada; Pierre P Massion; David P Carbone; Anil Shanker; Mikhail M Dikov
Journal:  J Immunother Cancer       Date:  2019-04-02       Impact factor: 13.751

6.  Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.

Authors:  Yasuhiko Ohshio; Koji Teramoto; Jun Hanaoka; Noriaki Tezuka; Yasushi Itoh; Tohru Asai; Yataro Daigo; Kazumasa Ogasawara
Journal:  Cancer Sci       Date:  2015-01-16       Impact factor: 6.716

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.